Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Regence and Tabula Rasa HealthCare (TRHC) have formed a strategic collaboration on a virtual clinical trial to study the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of novel coronavirus (Covid-19).
This clinical trial examines de-identified medical data for about 500,000 Regence health plan members across various business lines.
Regence is a family of health plans serving about 3.1 million members through its Regence health plans in Oregon, Idaho, Utah and Washington, while TRHC is an independent health care technology firm engaged in the field of medication safety.
Regence clinical services vice-president Julie Lindberg said: “Connecting members to care and supporting them through the Covid-19 pandemic is our highest priority.
“Through this partnership, we can help contribute to a long-term recovery plan that prioritises health and safety, while transparently sharing results that can aid other researchers working on strategies to combat Covid.”
For conducting the trial, theTRHC Precision Pharmacotherapy Research and Development Institute uses the multi-drug interaction technology solution MedWise to determine each patient’s MedWise Risk Score (MRS).
MRS is used as a predictive tool for adverse drug events.
TRHC Chairman and CEO Calvin H Knowlton said: “Partnering with Regence on this novel, virtual clinical trial supports TRHC’s commitment to provide the medical community with validated safety information on Covid-19 repurposed drugs.
“Our study will analyse the impact to members of adding each repurposed therapy, without exposing them to these drugs, and identify who is at increased risk for adverse drug events, further demonstrating the value of our MedWise technology across a large and diverse population including commercial and Medicare lives.”
According to the companies, the virtual clinical trial will also study the combined risk of increased ADEs for drug regimens with coronavirus repurposed adjuvants.
The results of this trial are expected to be available for publication within 60 days to add key coronavirus medication safety treatment information to the database.